Depixus in the news

We regularly participate in the world’s leading conferences on tools and technologies for biomolecular analysis and therapeutics. Look out for our presentations and come and say hello to learn more about MAGNA™ and its transformative potential for life sciences research and drug development.

Using MAGNA™ to explore drugs targeting RNA riboswitches

We’ve been working with Dr Jay Schneekloth, a leading expert in RNA-targeted drug discovery, to use our MAGNA™ technology to probe the interactions between the PreQ1 bacterial riboswitch and its natural ligand or a synthetic small molecule.

Read More

Depixus wins SLAS2024 Ignite Award for MAGNA™ technology

Paris, France – Depixus CEO Gordon Hamilton Receives The SLAS2024 Ignite Award From Judge Severine Tamas-Lhoustau, CEO Of Novoptim.

Read More

Depixus appoints  as Chief Commercial Officer to drive the commercialization of its groundbreaking MAGNA™ technology

PARIS, France – Interactomics pioneer Depixus has appointed experienced life sciences sales leader, Steve Klose, to the newly created role of Chief Commercial Officer from January 16, 2024. Klose will lead the company’s commercial growth strategy to build a highly effective sales and support organization, strengthening its market presence ahead of the commercial launch of its first laboratory instrument, MAGNA One™, in 2024.

Read More